First DOC1021 patients treated in Phase 1/2 refractory melanoma trial
DOC1021 enters a Phase 1/2 refractory melanoma trial testing personalised dendritic cell therapy without lymphodepletion or high-dose IL-2
Pharma & Biotech
Medical Devices & Diagnostics
Why New York approval could accelerate Quest Diagnostics’ Haystack MRD cancer strategy
Quest Diagnostics has taken Haystack MRD nationwide after New York approval. See how ctDNA testing could reshape cancer recurrence monitoring.